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Immunohistologic studies of8 patients with squamous cell 
carcinoma (See) were undertaken using a series of mono-
clonal antibodies. In all of the patients, over 70% of the 
dermal infiltrates reacted with OKT3 and OKIal (HLA-
DR), with a slight predominance of the OKT8+ suppres-
sor/cytotoxic T subset (the mean OKT4/0KT8 ratio was 
0.85). Both OKT4 + and OKT8+ subsets could be seen in 
contact with individual cancer cells. The percentage of 
OKB7 + (B) cells was less than 29% of the dermal infil-
trates. Some Leu-7+ cells (less than 9% of the infiltrates) 
V ariable degrees of inflammatory infiltrates surround-ing tumor cells are quite common findings in squa-mous cell carcinoma (SCC). This inflammatory re-action is composed of a large proportion of immunologically competent cells, and it has been 
postulated that these infiltrates play a role in an immunologic 
reaction against the tumor [1]. Some investigators have reported 
what they consider to be evidence of the mechanism against the 
tumor, such as mediated by activated macrophages [2], antibody-
mediated lymphocytotoxicity [3], and direct kill ing of tumor cells 
by activated lymphocytes [4,5]. Viac et al [1] reported that the 
lymphocytes liberated from tissue specimens ofSCC were mainly 
T cells . This finding has been confirmed using antisera directed 
against T cells and anti-immunoglobulin sera to identify B cells 
[6). Both groups of authors suggested that a T cell-mediated 
immune response was responsible for preventing spread of tumor. 
However, it has become clear that T cells cannot account for all 
aspects of resistance against tumor. It has been proved that natural 
killer (NK) cells play an important role in the resistance against 
tumors [7,8]. With the discovery of monoclonal antibodies (MCA) 
it is possible to identify immunologically competent cells. As far 
as we know, there have been no reports employing MCA that 
have discussed T-cell subsets and NK cells in lesions of SCc. 
The aim of this study was to further investigate the immu-
nohistologic features of SCC by means of MCA. 
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were seen in close association with individual cancer cells 
and none of these cells was present apart from the cancer 
cells. Few OKT6 + cells were observed in the papillary 
dermis and these had no relation to cancer cells. In the 
epidermis, OKT6 + dendritic cells remained within normal 
proportions . Staining with OKMl revealed sporadic re-
active cells. These results strongly suggest that besides T 
and B lymphocytes , Leu-7 + (natural killer) cells participate 
in a significant defense mechanism against see prolifer-
ation. ] lt1Vest D eY/natol 87:515-518, 1986 
MATERIALS AND METHODS 
Eight patients with SCC were studied. In all of the patients , the 
clinical diagnosis of SCC was confirmed by histologic exami-
nation of paraffin-embedded sections stained with hematoxylin-
eosin . No patients had immunologic abnormalities . 
For immunohistologic studies using MCA, operative speci-
mens were immediately frozen in liquid nitrogen and stored at 
- 60°C until used. Serial cryostat sections (4 ,lLm thickness) were 
air-dried, fixed in acetone for 10 min , and stained by the avidill-
biotin-peroxidase complex (ABC) method described elsewhere 
[9,10]. BrieRy, after blocking with normal horse serum diluted 
1:20 in 0.05 M Tris-HCI buffer (pH 7.6), the specimens were 
incubated with 1 :20 dilutions of OKT3, OKT4, OKT6, OKT8, 
OKB7, OKMl (Ortho Diagnostic Systems) , or biotin-conju-
gated Leu-7 (HNK1) (Beckton Dickinson), or a 1:100 dilution of 
OKlal (HLA-DR) (Ortho Diagnostic Systems) for 30 min. Then 
the slides were incubated sequentially with biotinylated horse 
antimouse IgG (Vector Laboratory) (all but the biotin-conjuga ted 
Leu-7) and ABC (Vector Laboratory) for 30 min . Washings be-
tween incubations were performed with Tris-HCl buffer (0.05 
M, pH 7.6) for 10 min. All antiserum incubations were performed 
in a humidified chamber at'room tempera ture. Peroxidase activity 
was revealed by incubation in 0.05 M Tris-HCl buffer (pH 7.6), 
0.05% 3,3'-diaminobenzidine tetrahydrochloride, and 0.01 % hy-
drogen peroxide for 5 min at room temperature. Finally, after 
counterstaining with hematoxylin, slides were dehydrated in a 
graded ethanol series, cleared in xylene, and mounted. 
In order to verify the specificity of Leu-7, it was applied to 
frozen tissue sections of tonsil , which has a well-known distri-
bution of NK cells [11] . 
The following negative controls were prepared: omission of 
primary antiserum, and nonimmune mouse serum as the first 
b~. . 
For each antibody , only cells displaying membrane staining 
were counted on all fields in 6 serial sections by means of an 
ocular square grid at 400 X magnification. At least 200 mono-
nuclear cells were counted to estimate the proportion of positive 
cells. 
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Table I. Monoclonal Antibody Studies of the Dermal Inftltrates in Lesions of Squamous Cell Carcinom a 
Case OKT3 OKT4 OKTS OKT4/0KTS HLA-DR OKB7 Lell-7 OKT6 OKM1 
1 S 5 4 1.2 10 3 Sporadic Sporadic 
2 9 6 4 1.5 10 2 1 Sporadic Sporadic 
3 9 4 6 0.6 10 2 Sporadic Sporadic 1 
4 9 4 6 0.6 10 2 Sporadic Sporadic 1 
5 10 5 6 O. S 10 1 Sporad ic Sporadic Sporadic 
6 10 4 7 0.5 10 1 Sporadic Sporadic Sporadic 
7 8 4 5 0.8 10 3 1 Sporadic Sporadic 
S 10 5 6 O.S 10 1 Sporadic Sporadic Sporadic 
T he results represent estim ated va lues; sporadi c. < 1 % o r cells stain ed; sco red 1 thro ugh 10, w here I rep resents 1-90/0 and 10 represents ~90o/o of cells stained. 
RESULTS 
Res ults are summarized in Table I. In all cases, over 70% of the 
dermal infilt rates reacted with pan T cell MCA OKT3 (Fig 1), 
and th ey were distributed diffusely throughout the dermis. Fur-
ther analysis of T-cell subsets w ithin the infdtrates revealed the 
presence of both the OKT4 + helper/inducer subset and the OKT8+ 
suppressor/cytotoxic subset. T he ratio ofOKT4 to OKT8 varied 
fro m 0.5-1.5 (mean 0.85). Conseq uentl y, this semiquantitative 
analysis showed that the OKT8+ subset (Fig 2) was present slightly 
more than the OKT4+ subset (Fig 3). Both subsets could be seen 
in contact with individual cancer cells. The proportion ofOKB7 + 
(B) cells was within 1-29% and many of th ese cells were dis-
tributed sli ghtly away from cancer cells. In all cases, over 80% 
of the dermal infi ltrates reacted with OKlal (HLA-DR) , but epi-
dermal keratinocytes and cancer cells did not express this antigen 
in our patients. 
The Leu-7+ cells were found in the germinal centers of sec-
ondary fo llicles in the tonsils. M ost of them werc~ stained along 
the cell membrane, but some of them also showed granular stain-
ing in the cytoplas m. In all cases with SCC, the Leu-7 + cells 
were seen in close association with individual ca ncer cells (Fig 4). 
N one of these cells was present apart fro m the cancer cells. The 
propor tion of these cells was small (less than 9% of the dermal 
infiltrates). In addition, th ere was a tendency for the proportion 
Figure 1. Cryostat section of a patient with Sec. Most of the dermal 
infi ltrates reacted with OKT3. Many of these cells are in con tact with the 
cancer cells ( x 200) . 
of Leu-7+ cells to increase with the depth of invasion of cancer 
cells. 
Staining wi th OKT6 revealed few reactive cells in the papillary 
dermis, and these cells w ere distributed with no relation to can cer 
cells. In the epidermis, OKT6 + dendritic cells remained within 
normal proportions . OKM 1'" cells w ere observed sporadically 
(less than 1 % of the derm al infi ltrates). In all cases, both nega tive 
control procedu res show ed negligible background staining . 
DISCUSSION 
Some investi gato rs using anti sera (6] or the E roset te test and the 
EAC rosette tes t (1] have reported the mononuclear cell infiltrates 
in SCC to be mainly T cells. These have also been overwhelming 
in their proportion in comparison to immunoglobulin-bearing 
cells. Our results confirmed these findings by means of highly 
specifi c M CA . In addition, we clarified the T-cell subsets in le-
sions ofSCC: although both OKT4 + cells and OKT8 + cells were 
observed, a slight predominance of the OKT8 + subset was re-
vealed (the T4/T8 ratio varied from 0.5-1.5, mean 0.85). Al-
though we found no correlation between the T4/T8 ratios and 
histo logic criteria (B roaders classification), there was a tendency 
for the T4/T8 ratios to increase with the duration of time up to 
operation. 
Since OKTS + cells can act as specific cytotoxic effectors in 
Figure 2. Cryostat section of a patient with SCc. Many of the cells 
reacted with OKTS ( x 200). 
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Figure 3. C ryostat section of a SCC lesion incubated with OKT4. Some 
positive cells are in contact with the cancer cells ( x 200). 
delayed-type hypersensitivity [12J , their presence therefore sug-
gests cell-mediated immunity as an immune mechanism of cy-
totoxicity. In addition, it is well known that class II (HLA-DR) 
antigen-specific cytotoxic T cells with the OKT4 + phenotype 
exist [13]. Thus it may be considered that OKTS + cells and some 
OKT4 + cells can act as cytotoxic effectors against SCc. Exper-
iments in mice using the in vitro cytotoxicity test have revealed 
the significance of Lytl - 2 + cells (e.g., Te) in tumor immunity 
[14,15]. Furthermore, the in vivo Tumor-Neutralizing test has 
shown that Lytl +2 - cells (e.g., T/-!, TDTI-I) as tumor-neutralizing 
effecto rs playa critical role in the rejection of tumors [1 6,17]. 
Therefore our immunohistologic findings indicate that both 
OKT4 + and OKTS + cells playa significant role in the defense 
mechanism against SCC. Although the number of OKBr (B) 
cells was small , these cells may playa role of partial interaction 
or synergism between the cell-mediated immune mechanism and 
immunoglobulin production against tumoral an tigens. 
Following staining with HLA-DR, we observed a vast number 
of HLA-DR + infiltrates accompanying the T-cell predominant 
populations. Since the number of OKB7 + cells was small, and 
OKT6 + cells and OKM1 + cells were negligible, it is considered 
that many of the infiltrates were activated T cells. Although we 
were unable to examine the stages of T-cell activation, we will 
be able to obtain more information in the future regarding the 
stages of the activated T cells using OKT9 [l S], OKT10 [l S], 
and TS2/7 [19] MCA. 
NK cells, a specialized subpopulation of lymp hoid cells iden-
tified by Leu-7 MCA [20], are thought to play an important role 
in the resistance to malignancy and viral infections [7,S]. There-
fore they should be expected to accumulate at the site of malignant 
cell proliferation. In fact, other authors [11, 21) have observed NK 
cells in the tumor tissues of Hodgkin's lymphoma, non-Hodg-
kin's lymphoma, hepatocarcinoma, breast cancer, lung cancer, 
and kidney carcinoma. In addition, these cells have frequently 
appeared to be in contact with tumor cells. Our previous study* 
showed that virtually no Leu-7 + cells existed in lesions of basal 
cell carcinoma (BCC). However, interestingly, we observed some 
Leu-7 + cells in all of our patients with SCC and these cells always 
existed in close association with individual cancer cells . It has 
been accepted that NK cell activity can be enhanced functionally 
*Kohchiyama A, Oka D, Ueki H: Expression of HLA-DR antigen 0 11 
tumor cells in lesions of basal cell ca rcinoma, submitted for publication. 
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Figure 4. When staining with Leu-7, a few positively stained cells are 
observed in close association with the cancer cells ( x 200). 
in the presence of interferons [22]. Since activated T cells produce 
y-interferon [23], it is possible that the NK cells in the ·lesions are 
activated by the activated T cells. Although many Leu-7 + cells 
(referred to as type A cells) lack T cell markers (T3 - , T11 - , T4 - , 
TS - ) but have substantial NK activity [24) and suppressor func-
tion [25], o ther Leu-7 + cells show the T8 + (Leu-2a +), T3 +, Tll + 
phenotypes (type B cells) with lower NK activity [26]. In addi-
tion, Abo et al [27] also established the presence of small amounts 
of Leu-7 +, T4 + (Leu-3a +), Tl1 + subsets (type C cells) . In this 
study, the possibility that Leu-7 + cells also reacted with OKT4 
or OKT8 MCA cannot be excluded. Although the proportion of 
Leu-7 + cells was small (less than 9% of the dermal infiltrates) in 
our patients, these cells were always seen in close association with 
individual cancer cells and I~one of them existed apart from the 
cancer cells. In addition , there was a tendency of Leu-7 + cells to 
increase with the depth of invasion of cancer cells. From these 
findings it is suggested that Leu-r (NK) cells playa role against 
tumor cell proliferation in lesions of SCC in cooperation with T 
cells. 
Langerhans cells (LC) possess important immunologic char-
acteristics: Fc-lgG and C3b receptors, HLA-DR antigens and an-
tigen-presentation ability [2SJ, and they have been accepted as 
playing an important role in the cellular immune reaction. It is 
also accepted that OKT6 MCA is highly specific for LC [29J. A 
marked hyperplasia of LC has been observed in the lesional and 
perilesional skin ofBCC [30,31], but we found few OKT6 + cells 
in the papillary dermis in lesions of SCC. In addition, these cells 
obviously were distributed with no relation to cancer cells. Al-
though participation of LC in SCC remains to be elucidated, our 
immunohistologic findings suggest that tumor immunity me-
diated by LC is not the main mechanism .against SCc. 
In conclusion, the results of this immunohistologic study of 
SCC employing MCA strongly suggest that besides T and B 
lymphocytes, Leu-r (NK) cells participate in a significant de-
fense mechanism against the proliferation of SCC. 
REFERENCES 
1. Viac J, Bustamante R, Thivolct J: Characterization of mononuclear 
cells in the inflammatory infiltrates of cutaneous tumors. Br J 
DermatoI97:1-10,1977 
2. Evans R, Alexander P: Mechanism of immunologically specific ki ll-
ing of tumor cells by macrophages. N ature 236:168-170, 1972 
518 KOHCHIYAMA, OKA AND U EKI 
3. Perl mann P, Perl mann H, Wigzell H: Lymphocyte mediated cyto-
tox.ity in vitro. Induction and inhibition by humoral antibody and 
nature of effector cells. Transplant Rev 13:91-114, 1972 
4. Hellstrom KE, Hellstrom I: Cellular immunity against tumor an-
tigens. Adv Cancer Res 12:167-223, 1969 
5. Hibbs ]B , Lambert LH, Remington ]S: Control of carcinogenesis: 
a possible role for the activated macrophage. Science 177:998-1000, 
1972 
6. De Panfilis G, Colli V, Manfredi G, Misk I, Rima] , Zampetti M , 
Allegra F: In situ identification of mononuclear cells infiltrating 
cutaneous carcinoma: an immuno-histochemical study. Acta Derm 
Venereol (Stockh) 59:219-222, 1979 
7. Herberman RB, Holden HT: Natural killer cells as antitumor effector 
cells. ]NCI 62:441-445, 1979 
8. Herberman RB, Ortaldo ]R: N atural killer cells: their role in defenses 
aga inst disease. Science 214:24-30, 1981 
9. Warnke R, Levy R: Detection of T and B cell antigens with hy-
bridoma monoclonal antibodies: a biotin-avidin-horseradish per-
oxidase method . ] Histochem Cytochem 28:771-776, 1980 
10. Hsu SM, Raine L, Fanger H : U se of avidin-biotin-peroxidase com-
plex (ABC) in immunoperoxidase techniques: a comparison be-
tween ABC and unlabeled antibody (PAP) procedures. ] Histo-
chem Cytochem 29:577-580, 1981 
11. Si L, Whiteside TL: Tissue distribution of human NK cells studied 
with anti-Leu-7 monoclonal antibody.] ImmunoI130:2149-2155, 
1983 
12. Wahlin B, Perln1ann P: Characterization of human K cells by surface 
antigens and morphology at the single cell level. J Immunol 
131:2340-2347,1983 
13. PobberJS, Collins T, Gimbrone MAJr, Cotran RS, GitlinJD, Fiers 
W, C layberger C, Krensky AM , Burakoff SJ, Reiss CS: Lym-
phocytes recognize human vascular endothelial and dermal fIbro-
blast Ia antigens induced by recombinant immune interferon. N a-
turc 305:726-729, 1983 
14. Gorczynski RM: Evidence for in vivo protection ~gainst murine-
sarcoma virus induced tumors by T lymphocytes from immune 
animals. J Immunol 11 2:533-539, 1974 
15. Simizu K, Shen FW: Role of different T cel l sets in the rejection ~f 
syngeneic chcmically induced tumors . J ImmunoI122:1 162-1165, 
1979 
16. Greenberg PD, C heever MA , Fefer A: Eradication of disseminated 
murine leukemia by chemoimmunotherapy with cyclophospha-
mide and adoptively transferred immune syngeneic Lytl +2- lym-
phocytes. J Exp Med 154:952-963, 1981 
17. Fukuzawa M, Fujiwara H , Yoshioka T, Itoh K, Hamaoka T: Effector 
cell analysis of tumor cell-rejection in vivo in two syngeneic tumor 
systems exhibiting distinct in vitro cytotoxic mechanisms. Gann 
75:912-919, 1984 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
18. Cotner T, Williams ]M, Christenson L, Shapiro HM, Strom TE, 
Strominger JL: Simultaneous flow cytometric analysis of human 
T cell activation, antigen expression and DNA content. J Exp 
Med 157:461-472, 1983 
19. Hemler ME, Sanchez-Madrid F, Flotte TJ, Krensky AM, Burakoff 
S], Bhan AK, Springer TA, StromingerJL: Glycoproteins of210,OOO 
and 130,000 M . W. on activated T cells: cell distribution and an-
tigenic relation to components on resting cells and T lines. J Im-
munoI132:3011-3018,1984 
20. Abo T, Balch CM: A differentiation antigen of human NK and K 
cells identified by a monoclonal antibody (HNK-l). J Immunol 
127:1024-1029, 1981 
21. Pizzolo G, Semenzato G, Chilosi M, Morittu L, Ambrosetti A, 
Warner N, Bofill M, Jannosy G: Distribution and heterogeneity 
of cells detected by HNK-1 monoclonal antibody in blood and 
tissues in normal, reactive and neoplastic conditions. Clin Exp 
Immunol 57:195-206, 1984 
22. Kato T, Minagawa T: Enhancement of cytotoxity of human pe-
ripheral blood lymphocytes by interferon. Microbiol lmmunol 
25:837-845, 1981 
23. Wheelock EF: Interferon-like virus inhibitor induced in human leu-
kocytes by phytohemagglutinin. Science 149:310-311, 1965 
24. Ortaldo JR, Sharrow SO, Timonen T, Herberman RB: Determi-
nation of surface antigens on highly purified human NK cells by 
flow cytometry with monoclonal antibodies. J Immunol 
127:2401-2409, 1981 
25. Tilden AB, Abo T, Balch CM: Suppressor cell function of human 
granular lymphocytes identified by the HNK-l (Leu-7) mono-
clonal antibody. J ImmunoI130:1171-1175, 1983 
26. Abo T, Cooper MD, Balch CM: Postnatal expansion of the natural 
killer and killer cell population in humans identified by the mono-
clonal HNK-1 antibody. J Exp Med 155:321-326, 1982 
27. Abo T, Miller CA, Gartland GL, Balch CM: Differentiation stages 
of human natural killer cells in lymphoid tissues from fetal to adult 
life. J Exp Med 157:273-284, 1983 
28. Wolff K, Stingl G: The Langerhans cells. J Inves t Dermatol 80 
(suppl):17s-21 s, 1983 
29. Dubertret L, Picard 0, Bagot M, Tulliez M, Fosse M, Aubert C , 
Touraine R: Specificity of monoclonal antibody anti-T-6 for Lan-
gerhans cells in normal human skin. Br J Dermatol 106:287-289, 
1982 
30. Macadam RF: An electron-microscopic study of basal cell carcinoma. 
J Pathol 126:149-156, 1978 
31. Murphy G, Krusinki PA , Myzak LA, Ershler WB: Local immt,lne 
response in basal cell carcinoma: characterization by transmission 
electron microscopy and monoclonal anti-T6 antibody. J Am Acad 
Dermatol 8:477-485, 1983 
